|[January 14, 2013]
Research and Markets: EpiCast Report: Epilepsy Epidemiology Forecast to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/k87884/epicast_report)
has announced the addition of GlobalData's new report "EpiCast Report:
Epilepsy Epidemiology Forecast to 2022" to their offering.
Epilepsy affects 50 million people worldwide each year and is one of the
most common neurological conditions in the world (WHO, 2005). Epilepsy
is defined as a collection of brain dysfunction disorders characterized
by recurrent and unpredictable seizures. The prevalence of epilepsy
varies among countries due to a mosaic of economic, political, and
social differences. Epidemiologists expect that the number of active and
lifetime prevalent cases of epilepsy will increase during the forecast
period (2012-2022) in the nine markets covered. In 2012, we estimate
that there was a total of 17,542,651 active prevalent cases of epilepsy
in the nine markets, and GlobalData epidemiologists forecast that by
2022, the number of active prevalent cases will grow to 18,565,967. A
major strength of this analysis is that the forecast methodology was
consistent across the nine markets to allow for a meaningful comparison
of the patient populations in each country.
- The Epilepsy EpiCast Report and EpiCast Model provide an overview of
risk factors and global trends for epilepsy.
- Data is provided for the seven major markets (the US, France, Germany,
Italy, Spain, the UK, and Japan) along with emerging marketsIndia and
- It includes a 10-year epidemiological forecast of active and lifetime
prevalent cases of epilepsy segmented by gender, age, treatment gap, and
seizure type (generalized, partial, and unknown).
Reasons to buy
- Develop business strategies by understanding the trends shaping and
driving the global epilepsy market.
- Quantify patient populations in the global epilepsy market to improve
product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the epilepsy
gender, age groups, and seizure types (generalized, partial, and
unknown) that present the best opportunities for epilepsy therapeutics
in each of the markets covered.
For more information visit http://www.researchandmarkets.com/research/k87884/epicast_report
Source (News - Alert): GlobalData
[ Back To Technology News's Homepage ]